Edition:
United States

Tigenix NV (G9U.BR)

G9U.BR on Brussels Stock Exchange

1.01EUR
11:35am EDT
Change (% chg)

€0.00 (+0.10%)
Prev Close
€1.01
Open
€1.01
Day's High
€1.02
Day's Low
€1.00
Volume
301,479
Avg. Vol
509,693
52-wk High
€1.06
52-wk Low
€0.64

Latest Key Developments (Source: Significant Developments)

Tigenix H1 operating loss widens to 13.1 million euros
Tuesday, 20 Sep 2016 01:26am EDT 

Tigenix NV : H1 operating loss 13.1 million euros ($14.64 million) versus loss of 9.6 million euros year ago . H1 total revenues 943,000 euros versus 938,000 euros year ago . H1 loss for the period 9.4 million euros versus loss of 10.6 million euros year ago .Cash position at June 30, 2016 of 24.1 million euros.  Full Article

Tigenix announces publication in lancet of 24-week results of phase 3 admire-cd trial investigating CX601
Tuesday, 2 Aug 2016 02:00am EDT 

Tigenix Nv : Announces publication in lancet of 24-week results of phase 3 admire-cd trial investigating CX601 in treatment of complex perianal fistulas in patients with crohn's disease . A pivotal phase 3 trial for CX601 for treatment of complex perianal fistulas is expected to start in United States in 2017 .In U.S., Tigenix intends to apply for fast track designation from U.S. Food and drug administration (FDA).  Full Article

Cormorant Asset Management notifies 5.81 pct shareholding in Tigenix
Wednesday, 20 Jul 2016 01:03am EDT 

Tigenix Nv :Tigenix: Cormorant Asset Management, LLC notifies 5.81 pct shareholding in Tigenix.  Full Article

TiGenix and Takeda enter into licensing agreement for ex-U.S. Rights to CX601
Tuesday, 5 Jul 2016 02:06am EDT 

TiGenix NV : Takeda <4502.T> and TiGenix enter into licensing agreement for ex-u.s. Rights to CX601 for treatment of complex perianal fistulas in patients with crohn's disease . TiGenix will receive an upfront cash payment of 25 million euros ($27.8 million) . TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of 355 million euros and double digit royalties on net sales by Takeda . First anticipated milestone payment is 15 million euros upon obtaining marketing authorization of CX601 in European Economic Area (EEA) .In addition, takeda will make an equity investment of 10 million euros in share capital of Tigenix within next 12 months.  Full Article

Tigenix to present positive phase III CX601 results
Wednesday, 18 May 2016 01:00am EDT 

Tigenix NV :CX601 positive phase III results to be presented at digestive disease week in the USA.  Full Article

Tigenix selects TFS for clinical trial
Monday, 18 Apr 2016 08:00pm EDT 

Tigenix NV:Selects TFS for the first clinical trial to treat severe sepsis with allogeneic expanded adipose-derived stem cells.  Full Article

Tigenix presents update of CX601 phase III trial
Thursday, 17 Mar 2016 02:00am EDT 

Tigenix NV:Tigenix presents 24 week results of its CX601 phase III trial at ECCO 2016.  Full Article

Tigenix U.S. IPO not yet launched
Wednesday, 9 Mar 2016 01:35pm EST 

Tigenix NV:Said on Wednesday it has not yet launched and IPO of its American Depository Shares (ADSs) due to unfavourable capital market conditions.Company continues to evaluate the most appropriate timing for launching the initial public offering as market conditions develop.  Full Article

Tigenix to raise 15 mln euro via private placement
Wednesday, 9 Mar 2016 01:19pm EST 

Tigenix NV:Announces launch of private placement to raise target amount of about 15 million euros with institutional investors.  Full Article

Tigenix announces positive 52-week Phase III results of Cx601
Sunday, 6 Mar 2016 07:00pm EST 

Tigenix NV:Announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients.Results confirm the favorable safety and tolerability profile of Cx601 already reported at week 24.  Full Article

BRIEF-Tigenix H1 operating loss widens to 20.5 million euros

* H1 OPERATING LOSS EUR 20.5 MILLION VERSUS LOSS OF EUR 13.1 MILLION YEAR AGO